


 Cite this: *RSC Adv.*, 2024, 14, 25077

Correction: Study on mechanism of elemene reversing tumor multidrug resistance based on luminescence pharmacokinetics in tumor cells *in vitro* and *in vivo*

 Liying Chen,^a Zhi Chen,^{*ab} Shuang Zheng,^a Luhui Fan,^a Lixin Zhu,^{ac} Jiandong Yu,^a Chaoyuan Tang,^a Qi Liu^d and Yang Xiong^{*a}

DOI: 10.1039/d4ra90085e

rsc.li/rsc-advances

 Correction for 'Study on mechanism of elemene reversing tumor multidrug resistance based on luminescence pharmacokinetics in tumor cells *in vitro* and *in vivo*' by Liying Chen *et al.*, *RSC Adv.*, 2020, 10, 34928–34937, <https://doi.org/10.1039/d0ra00184h>.

The authors regret that due to an image selection and processing error, the panel of group B-53 min and group C-93 min were incorrect in Fig. 4. The corrected version of Fig. 4 is provided below:


^aDepartment of Pharmaceutical Science, College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 311400, Zhejiang, China

^bThe First People's Hospital of Jiande, Jiande 311600, Zhejiang, China

^cZhejiang Institute for Food and Drug Control, Hangzhou 310004, Zhejiang, China

^dDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA




Fig. 4 BLI of MCF-7/DOX^{Fluc} tumor-bearing nude mice at different time points within 115 min after intraperitoneal injected D-luc with a dose of 100 mg kg⁻¹ ($n = 3$). (A) PBS group (i.p., QD). (B) The low ELE concentration group (ELE 10 mg kg⁻¹, i.p., QD). (C) The high ELE concentration group (ELE 25 mg kg⁻¹, i.p., QD).

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

